сгенерировать QR код
Открытый доступ
Только для подписчиков
IS PIVKA-II A PROMISING BIOMARKER FOR HEPATOCELLULAR CARCINOMA?
https://doi.org/10.17021/2020.15.1.6.9
Аннотация
Aim. To evaluate the clinical contribution of protein induced by vitamin K absence (PIVKA-II) for the diagnosis of hepatocellular carcinoma (HCC). The second aim was to compare PIVKA-II with routinely used alpha-fetoprotein (AFP) for the same indication. Materials and methods. 310 participants were enrolled in our study: 60 with HCC, 40 with liver metastases of colorectal cancer origin, 40 with liver cirrhosis, 20 with pancreatic cancer (PC) and 150 healthy individuals. Serum levels of PIVKA-II were measured using a chemiluminescent assay of the Architect 1000i System (“Abbott”, USA) and AFP levels using a chemiluminescent assay by DxI 800 (“Beckman Coulter”, USA). Serum concentrations of PIVKA-II and AFP were compared between the group with HCC and the other mentioned groups. Results. PIVKA-II achieved better clinical sensitivity in comparison with AFP. PIVKA-II achieved its best sensitivity (96,9 %) in distinguishing between the HCC and control group with the proposed cut-off value of 60 mAU/ml. Conclusion. PIVKA-II can be used alongside routinely established AFP as a valuable marker in the diagnosis of HCC.
Об авторах
P. Broz
University Hospital and Faculty of Medicine in Pilsen, Charles University; Institute of Clinical Biochemistry and Haematology, University Hospital in Pilsen
Россия
Россия
S. Svobodova
University Hospital and Faculty of Medicine in Pilsen, Charles University
Россия
Россия
M. Karlíkova
University Hospital and Faculty of Medicine in Pilsen, Charles University
Россия
Россия
O. Topolcan
University Hospital and Faculty of Medicine in Pilsen, Charles University
Россия
Россия
V. Treska
University Hospital and Faculty of Medicine in Pilsen, Charles University
Россия
Россия
R. Kucera
University Hospital and Faculty of Medicine in Pilsen, Charles University
Россия
Россия
Список литературы
1. Asrih M., Jornayvaz F. R. Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link? Mol. Cell. Endocrinol., 2015, vol. 418, Pt. 1, pp. 55-65.
2. Effendi K., Sakamoto M. Molecular pathology in early hepatocarcinogenesis. Oncology, 2010, vol. 78, no. 2, pp. 157-160.
3. El-Serag H. B. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology, 2012, vol. 142, no. 6, pp. 1264-1273.
4. Ertle J. M., Heider D., Wichert M., Keller B., Kueper R., Hilgard P., Gerken G., Schlaak J. F. A combination of α-fetoprotein and des-γ-carboxy prothrombin is superior in detection of hepatocellular carcinoma. Digestion, 2013, vol. 87, no. 2, pp. 121-131.
5. Jang E. S., Jeong S. H., Kim J.W., Choi Y. S., Leissner P., Brechot C. Diagnostic Performance of Alpha-Fetoprotein, Protein Induced by Vitamin K Absence, Osteopontin, Dickkopf-1 and Its Combinations for Hepatocellular Carcinoma. PLoS One, 2016, vol. 11, no. 3, e0151069. doi: 10.1371/journal.pone.0151069.
6. Kucera R., Topolcan O., Fiala O., Kinkorova J., Treska V., Zedníková I., Slouka D., Simanek V., Safanda M., Babuska V. The Role of TPS and TPA in the Diagnostics of Distant Metastases. Anticancer Res., 2016, vol. 36, no. 2, pp. 773-777.
7. Lefrere J. J., Gozin D. Use of des-gamma-carboxyprothrombin in retrospective diagnosis of hidden intoxication of anticoagulants. J. Clin. Pathol., 1987, vol. 40, no. 5, pp. 589.
8. Ludvík J., Duras P., Třeška V., Matoušková T., Brůha J., Fichtl J., Lysák D., Ferda J., Baxa J. Portal Vein Embolization with Contralateral Application of Stem Cells Facilitates Increase of Future Liver Remnant Volume in Patients with Liver Metastases. Cardiovasc. Intervent. Radiol., 2017, vol. 40, no. 5, pp. 690-696.
9. Nakamura S., Nouso K., Sakaguchi K., Ito Y. M., Ohashi Y., Kobayashi Y., Toshikuni N., Tanaka H., Miyake Y., Matsumoto E., Shiratori Y. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am. J. Gastroenterol., 2006, vol. 101, no. 9, pp. 2038-2043.
10. Nguyen-Dinh S. H., Do A., Pham T. N. D., Dao D. Y., Nguy T. N., Chen M. S. Jr. High burden of hepatocellular carcinoma and viral hepatitis in Southern and Central Vietnam: Experience of a large tertiary referral center, 2010 to 2016. World. J. Hepatol., 2018, vol. 10, no. 1, pp. 116-123.
11. Nomura F., Ishijima M., Kuwa K., Tanaka N., Nakai T., Ohnishi K. Serum des-gamma-carboxy prothrombin levels determined by a new generation of sensitive immunoassays in patients with small-sized hepatocellular carcinoma. Am. J. Gastroenterol., 1999, vol. 94, no. 3, pp. 650-654.
12. Okuda H., Nakanishi T., Takatsu K., Saito A., Hayashi N., Takasaki K., Takenami K., Yamamoto M., Nakano M. Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma. Cancer, 2000, vol. 88, no. 3, pp. 544-549.
13. Poté N., Cauchy F., Albuquerque M., Voitot H., Belghiti J., Castera L., Puy H., Bedossa P., Paradis V. Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion. J. Hepatol., 2015, vol. 62, no. 4, pp. 848-854.
14. Seo S. I., Kim H. S., Kim W. J., Shin W. G., Kim D. J., Kim K. H., Jang M. K., Lee J. H., Kim J. S., Kim H. Y., Kim D. J., Lee M. S., Park C. K. Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma. World J. Gastroenterol., 2015, vol. 21, no. 13, pp. 3928-3935.
15. Siegel R. L., Miller K. D., Jemal A. Cancer statistics, 2016. CA Cancer J. Clin., 2016, vol. 66, no. 1, pp. 7-30.
16. Siriwardana R. C., Niriella M. A., Dassanayake A., Ediriweera D., Gunetilleke B., Sivasundaram T., de Silva J. Association of Serum Ferritin with Diabetes and Alcohol in Patients with Non-Viral Liver Disease-Related Hepatocellular Carcinoma. Liver Cancer, 2017, vol. 6, no. 4, pp. 307-312.
17. Sultanik P., Ginguay A., Vandame J., Popovici T., Meritet J. F., Cynober L., Pol S., Bories P. N. Diagnostic accuracy of des-gamma-carboxy prothrombin for hepatocellular carcinoma in a French cohort using the Lumipulse® G600 analyzer. J. Viral Hepat., 2017, vol. 24, no. 1, pp. 80-85.
18. Tartaglione S., Pecorella I., Zarrillo S. R., Granato T., Viggiani V., Manganaro L., Marchese C., Angeloni A., Anastasi E. Protein Induced by Vitamin K Absence II (PIVKA-II) as a potential serological biomarker in pancreatic cancer: a pilot study. Biochem. Med. (Zagreb), 2019, vol. 29, no. 2, pp. 020707.
19. Treska V., Fichtl J., Bruha J., Liska V., Kormunda S., Finek J. Liver Resections for Colorectal Metastases in Patients Aged Over 75 Years. Anticancer Res., 2017, vol. 37, no. 3, pp. 1529-1533.
20. Viggiani V., Palombi S., Gennarini G., D’Ettorre G., De Vito C., Angeloni A., Frati L., Anastasi E. Protein induced by vitamin K absence or antagonist-II (PIVKA-II) specifically increased in Italian hepatocellular carcinoma patients. Scand. J. Gastroenterol., 2016, vol. 51, no. 10, pp. 1257-1262.
21. Wang X., Zhang W., Liu Y., Gong W., Sun P., Kong X., Yang M., Wang Z. Diagnostic value of prothrombin induced by the absence of vitamin K or antagonist-II (PIVKA-II) for early stage HBV related hepatocellular carcinoma. Infect. Agent. Cancer, 2017, vol. 12. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5569466/ (accessed 16 July 2019).
22. Yang J. D., Roberts L. R. Hepatocellular carcinoma: A global view. Nat. Rev. Gastroenterol. Hepatol., 2010, vol. 7, no. 8, pp. 448-458.
23. Yu R., Ding S., Tan W., Tan S., Tan Z., Xiang S., Zhou Y., Mao Q., Deng G. Performance of Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) for Hepatocellular Carcinoma Screening in Chinese Population. Hepat. Mon. 2015, vol. 15, no. 7. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4539732/ (accessed 16 July 2019).
24. Zakhary N. I., Khodeer S. M., Shafik H. E., Abdel Malak C. A. Impact of PIVKA-II in diagnosis of hepatocellular carcinoma. J. Adv. Res., 2013, vol. 4, no. 6, pp. 539-546.
Рецензия
Для цитирования:
, , , , , . Астраханский медицинский журнал. 2020;15(1):6-9. https://doi.org/10.17021/2020.15.1.6.9
For citation:
Broz P., Svobodova S., Karlíkova M., Topolcan O., Treska V., Kucera R. IS PIVKA-II A PROMISING BIOMARKER FOR HEPATOCELLULAR CARCINOMA? Astrakhan medical journal. 2020;15(1):6-9. (In Russ.) https://doi.org/10.17021/2020.15.1.6.9
Просмотров:
173
Послать статью по эл. почте 